Relative survival in patients with cancer and kidney failure
Nephrology Dialysis Transplantation · 2024
DOI: 10.1093/ndt/gfae046 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2024. Verfasst von Laia Oliveras und 6 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. Hauptthemen laut MEDLINE: Neoplasms, Renal Dialysis, Kidney Transplantation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Sociedad Española de Nefrología, NHMRC.
Abstract (Originalsprache)
Background
The population with kidney failure is at increased risk of cancer and associated mortality. Relative survival can provide insight into the excess mortality, directly or indirectly, attributed to cancer in the population with kidney failure.
Methods
We estimated relative survival for people all ages receiving dialysis (n = 4089) and kidney transplant recipients (n = 3253) with de novo cancer, and for the general population with cancer in Australia and New Zealand (n = 3 043 166) over the years 1980–2019. The entire general population was the reference group for background mortality, adjusted for sex, age, calendar year and country. We used Poisson regression to quantify excess mortality ratios.
Results
Five-year relative survival for all-site cancer was markedly lower than that for the general population for people receiving dialysis [0.25, 95% confidence interval (CI) 0.23–0.26] and kidney transplant recipients (0.55, 95% CI 0.53–0.57). In dialysis, excess mortality was more than double (2.16, 95% CI 2.08–2.25) that of the general population with cancer and for kidney transplant recipients 1.34 times higher (95% CI 1.27–2.41). There was no difference in excess mortality from lung cancer between people with kidney failure and the general population with cancer. Comparatively, there was a significant survival deficit for people with kidney failure, compared with the general population with cancer, for melanoma, breast cancer and prostate cancers.
Conclusion
Decreased cancer survival in kidney failure may reflect differences in multi-morbidity burden, reduced access to treatment, or greater harm from or reduced efficacy of treatments. Our findings support research aimed at investigating these hypotheses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nephrology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
- Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
- Kirby Institute, UNSW Sydney, Kensington, NSW, Australia.
- NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia.
ORCID-Profile: Laia Oliveras, Nicole De La Mata, Nuria Montero
Förderung
- Sociedad Española de Nefrología
- NHMRC
Zitieren
APA
Oliveras, L., Rosales, B. M., De La Mata, N., Vajdic, C. M., Montero, N., Cruzado, J. M., & Webster, A. C. (2024). Relative survival in patients with cancer and kidney failure. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfae046
Vancouver
Oliveras L, Rosales BM, De La Mata N, Vajdic CM, Montero N, Cruzado JM, et al. Relative survival in patients with cancer and kidney failure. Nephrology Dialysis Transplantation. 2024. doi:10.1093/ndt/gfae046
BibTeX
@article{Oliveras2024,
author = {Oliveras, Laia and Rosales, Brenda Maria and De La Mata, Nicole and Vajdic, Claire M and Montero, Nuria and Cruzado, Josep M and Webster, Angela C},
title = {Relative survival in patients with cancer and kidney failure},
journal = {Nephrology Dialysis Transplantation},
year = {2024},
doi = {10.1093/ndt/gfae046}
}
EUVIMED